2022
Population-Level Strategies for Nirmatrelvir/Ritonavir Prescribing—A Cost-effectiveness Analysis
Savinkina A, Paltiel A, Ross J, Gonsalves G. Population-Level Strategies for Nirmatrelvir/Ritonavir Prescribing—A Cost-effectiveness Analysis. Open Forum Infectious Diseases 2022, 9: ofac637. PMID: 36589482, PMCID: PMC9792084, DOI: 10.1093/ofid/ofac637.Peer-Reviewed Original ResearchCost-effectiveness analysisTrade-offs implicitSevere diseaseDecision analytic modelAllocation decisionsPay thresholdsPolicy strategiesUnvaccinated patientsVaccination statusHigh riskTreatment effectivenessHigh-risk individualsAllocation strategyPopulation-level strategiesWillingnessFurther priorityDrug costsSensitivity analysisCostRitonavir treatmentUnvaccinated personsVaccinated adultsPatient populationClinical trialsLower risk
2004
Association between preference-based health-related quality of life and asthma severity
Moy ML, Fuhlbrigge AL, Blumenschein K, Chapman RH, Zillich AJ, Kuntz KM, Paltiel AD, Kitch BT, Weiss ST, Neumann PJ. Association between preference-based health-related quality of life and asthma severity. Annals Of Allergy Asthma & Immunology 2004, 92: 329-334. PMID: 15049396, DOI: 10.1016/s1081-1206(10)61570-0.Peer-Reviewed Original ResearchConceptsPreference-based measuresHealth Utilities Index 3Standard gambleAsthma Symptom Utility IndexTime tradeoffPreference-based health-related qualityResource allocation decisionsHealth statesCost-effectiveness analysisStrength of preferenceSubject's health stateAllocation decisionsAsthma severityHealth-related qualityValues peoplePreference scoresPreference instrumentSymptom frequencyRating ScaleUtility indexAirway obstructionLung functionHUI3 scoresHealth improvementPreferences